Author: "Punt, C." / Search Limiters: Available in Library Collection - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Punt, C."' showing total 332 results

Start Over Author "Punt, C." Search Limiters Available in Library Collection

332 results on '"Punt, C."'

1. FOxTROT2: innovative trial design to evaluate the role of neoadjuvant chemotherapy for treating locally advanced colon cancer in older adults or those with frailty

Author: Platt, J.R., Todd, O.M., Hall, P., Craig, Z., Quyn, A., Seymour, M., Braun, M., Roodhart, J., Punt, C., Christou, N., Taieb, J., Karoui, M., Brown, J., Cairns, D.A., Morton, D., Gilbert, A., and Seligmann, J.F.
Published: 2023
Full Text: View/download PDF

2. First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study

Author: Van Cutsem, E., Danielewicz, I., Saunders, M. P., Pfeiffer, P., Argilés, G., Borg, C., Glynne-Jones, R., Punt, C. J. A., Van de Wouw, A. J., Fedyanin, M., Stroyakovskiy, D., Kroening, H., Garcia-Alfonso, P., Wasan, H., Falcone, A., Fougeray, R., Egorov, A., Amellal, N., and Moiseyenko, V.
Published: 2022
Full Text: View/download PDF

3. Modulation of Hypoxia in Murine Liver Metastases of Colon Carcinoma by Nicotinamide and Carbogen

Author: van Laarhoven, H. W. M., Bussink, J., Lok, J., Verhagen, I., Punt, C. J. A., Heerschap, A., and van der Kogel, A. J.
Published: 2005

4. Interconnectivity between molecular subtypes and tumor stage in colorectal cancer

Author: Coebergh van den Braak, R. R. J., ten Hoorn, S., Sieuwerts, A. M., Tuynman, J. B., Smid, M., Wilting, S. M., Martens, J. W. M., Punt, C. J. A., Foekens, J. A., Medema, J. P., IJzermans, J. N. M., and Vermeulen, L.
Published: 2020
Full Text: View/download PDF

5. Perioperative Systemic Therapy Versus Cytoreductive Surgery and HIPEC Alone for Resectable Colorectal Peritoneal Metastases: Patient-Reported Outcomes of a Randomized Phase II Trial

Author: Bakkers, C., Rovers, K. P., Rijken, A., Simkens, G. A.A.M., Bonhof, C. S., Nienhuijs, S. W., Burger, J. W.A., Creemers, G. J.M., Brandt-Kerkhof, A. R.M., Tuynman, J. B., Aalbers, A. G.J., Wiezer, M. J., de Reuver, P. R., van Grevenstein, W. M.U., Hemmer, P. H.J., Punt, C. J.A., Tanis, P. J., Mols, F., de Hingh, I. H.J.T., Thijs, A. M.J., Lurvink, R. J., Madsen, E. V.E., van Meerten, E., Kusters, M., Versteeg, K. S., Kok, N. F.M., Buffart, T. E., Boerma, D., Los, M., de Wilt, J. H.W., Verheul, H. M.W., Kruijff, S., de Groot, D. J.A., Koopman, M., Surgery, Medical Oncology, Hematology, Gastroenterology & Hepatology, Psychiatry, and Erasmus MC other
Abstract: Background: As part of a randomized phase II trial in patients with isolated resectable colorectal peritoneal metastases (CPMs), the present study compared patient-reported outcomes (PROs) of patients treated with perioperative systemic therapy versus cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS–HIPEC) alone. Also, PROs of patients receiving perioperative systemic therapy were explored. Patients and Methods: Eligible patients were randomized to perioperative systemic therapy (experimental) or CRS–HIPEC alone (control). PROs were assessed using EORTC QLQ-C30, QLQ-CR29, and EQ-5D-5L questionnaires at baseline, after neoadjuvant treatment (experimental), and at 3 and 6 months postoperatively. Linear mixed modeling was used to compare five predefined PROs (visual analog scale, global health status, physical functioning, fatigue, C30 summary score) between arms and to longitudinally analyze PROs in the experimental arm. Results: Of 79 analyzed patients, 37 (47%) received perioperative systemic therapy. All predefined PROs were comparable between arms at all timepoints and returned to baseline at 3 or 6 months postoperatively. The experimental arm had worsening of fatigue [mean difference (MD) + 14, p = 0.001], loss of appetite (MD + 15, p = 0.003), hair loss (MD + 18, p < 0.001), and loss of taste (MD + 27, p < 0.001) after neoadjuvant treatment. Except for loss of appetite, these PROs returned to baseline at 3 or 6 months postoperatively. Conclusions: In patients with resectable CPM randomized to perioperative systemic therapy or CRS–HIPEC alone, PROs were comparable between arms and returned to baseline postoperatively. Together with the trial’s previously reported feasibility and safety data, these findings show acceptable tolerability of perioperative systemic therapy in this setting.
Published: 2023

6. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Author: Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J.H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., Ciardiello, F., D'Hoore, A., Diaz-Rubio, E., Douillard, J.-Y., Ducreux, M., Falcone, A., Grothey, A., Gruenberger, T., Haustermans, K., Heinemann, V., Hoff, P., Köhne, C.-H., Labianca, R., Laurent-Puig, P., Ma, B., Maughan, T., Muro, K., Normanno, N., Österlund, P., Oyen, W.J.G., Papamichael, D., Pentheroudakis, G., Pfeiffer, P., Price, T.J., Punt, C., Ricke, J., Roth, A., Salazar, R., Scheithauer, W., Schmoll, H.J., Tabernero, J., Taïeb, J., Tejpar, S., Wasan, H., Yoshino, T., Zaanan, A., and Arnold, D.
Published: 2016
Full Text: View/download PDF

7. Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases – the multicenter randomized controlled PUMP trial

Author: Buisman, F. E., Homs, M. Y. V., Grünhagen, D. J., Filipe, W. F., Bennink, R. J., Besselink, M. G. H., Borel Rinkes, I. H. M., Bruijnen, R. C. G., Cercek, A., D’Angelica, M. I., van Delden, O. M., Donswijk, M. L., van Doorn, L., Doornebosch, P. G., Emmering, J., Erdmann, J. I., IJzerman, N. S., Grootscholten, C., Hagendoorn, J., Kemeny, N. E., Kingham, T. P., Klompenhouwer, E. G., Kok, N. F. M., Koolen, S., Kuhlmann, K. F. D., Kuiper, M. C., Lam, M. G. E., Mathijssen, R. H. J., Moelker, A., Oomen-de Hoop, E., Punt, C. J. A., te Riele, W. W., Roodhart, J. M. L., Swijnenburg, R. J., Prevoo, W., Tanis, P. J., Vermaas, M., Versleijen, M. W. J., Veuger, F. P., Weterman, M. J., Verhoef, C., and Groot Koerkamp, B.
Published: 2019
Full Text: View/download PDF

8. Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study

Author: Goey, K. K. H., Elias, S. G., van Tinteren, H., Laclé, M. M., Willems, S. M., Offerhaus, G. J. A., de Leng, W. W. J., Strengman, E., ten Tije, A. J., Creemers, G.-J. M., van der Velden, A., de Jongh, F. E., Erdkamp, F. L. G., Tanis, B. C., Punt, C. J. A., and Koopman, M.
Published: 2017
Full Text: View/download PDF

9. How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials

Author: Bonnetain, F., Borg, C., Adams, R. R., Ajani, J. A., Benson, A., Bleiberg, H., Chibaudel, B., Diaz-Rubio, E., Douillard, J. Y., Fuchs, C. S., Giantonio, B. J., Goldberg, R., Heinemann, V., Koopman, M., Labianca, R., Larsen, A. K., Maughan, T., Mitchell, E., Peeters, M., Punt, C. J. A., Schmoll, H. J., Tournigand, C., and de Gramont, A.
Published: 2017
Full Text: View/download PDF

10. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004)

Author: Ruers, T., Punt, C., Van Coevorden, F., Pierie, J.P.E.N., Borel-Rinkes, I., Ledermann, J.A., Poston, G., Bechstein, W., Lentz, M.A., Mauer, M., Van Cutsem, E., Lutz, M.P., and Nordlinger, B.
Published: 2012
Full Text: View/download PDF

11. The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis

Author: Dias, M M, Pignon, J-P, Karapetis, C S, Boige, V, Glimelius, B, Kweekel, D M, Lara, P N, Laurent-Puig, P, Martinez-Balibrea, E, Páez, D, Punt, C J A, Redman, M W, Toffoli, G, Wadelius, M, McKinnon, R A, and Sorich, M J
Published: 2014
Full Text: View/download PDF

12. Management of isolated nonresectable liver metastases in colorectal cancer patients: a case–control study of isolated hepatic perfusion with melphalan versus systemic chemotherapy

Author: van Iersel, L.B.J., Koopman, M., van de Velde, C.J.H., Mol, L., van Persijn van Meerten, E.L., Hartgrink, H.H., Kuppen, P.J.K., Vahrmeijer, A.L., Nortier, J. W. R, Tollenaar, R.A.E.M., Punt, C., and Gelderblom, H.
Published: 2010
Full Text: View/download PDF

13. O-8 Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer

Author: André, T., primary, Shiu, K., additional, Kim, T., additional, Jensen, B., additional, Jensen, L., additional, Punt, C., additional, Smith, D., additional, Garcia-Carbonero, R., additional, Alcaide García, J., additional, Gibbs, P., additional, De la Fouchardière, C., additional, Rivera Herrero, F., additional, Elez, E., additional, Bendell, J., additional, Le, D., additional, Yoshino, T., additional, Zhong, W., additional, Fogelman, D., additional, Marinello, P., additional, and Diaz, L., additional
Published: 2021
Full Text: View/download PDF

14. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial†

Author: Breugom, A. J., van Gijn, W., Muller, E. W., Berglund, Å., van den Broek, C. B. M., Fokstuen, T., Gelderblom, H., Kapiteijn, E., Leer, J. W. H., Marijnen, C. A. M., Martijn, H., Meershoek-Klein Kranenbarg, E., Nagtegaal, I. D., Påhlman, L., Punt, C. J. A., Putter, H., Roodvoets, A. G. H., Rutten, H. J. T., Steup, W. H., Glimelius, B., and van de Velde, C. J. H.
Published: 2015
Full Text: View/download PDF

15. Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer

Author: Peeters, M., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., André, T., Chan, E., Lordick, F., Punt, C. J. A., Strickland, A. H., Wilson, G., Ciuleanu, T. E., Roman, L., Van Cutsem, E., Tian, Y., and Sidhu, R.
Published: 2014
Full Text: View/download PDF

16. Dendritic cell vaccination and immune monitoring

Author: Aarntzen, E. H. J. G., Figdor, C. G., Adema, G. J., Punt, C. J. A., and de Vries, I. J. M.
Published: 2008
Full Text: View/download PDF

17. In situ detection of antigen-specific T cells in cryo-sections using MHC class I tetramers after dendritic cell vaccination of melanoma patients

Author: De Vries, I. J. M., Bernsen, M. R., van Geloof, W. L., Scharenborg, N. M., Lesterhuis, W. J., Rombout, P. D. M., Van Muijen, G. N. P., Figdor, C. G., Punt, C. J. A., Ruiter, D. J., and Adema, G. J.
Published: 2007
Full Text: View/download PDF

18. Health-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Phase III KEYNOTE-177 study

Author: Andre, T., Amonkar, M., Norquist, J., Shiu, K-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C. J., Smith, D., Garcia-Carbonero, R., Sevilla, I., de la Fouchardiere, C., Rivera, F., Elez, E., Diaz, L. A., Yoshino, T., Van Cutsem, E., Yang, P., Farooqui, M. Z. H., and Le, D.
Published: 2020

19. Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands

Author: Kwakman, Johannes J.M., Vink, G., Vestjens, J. H., Beerepoot, L. V., de Groot, J. W., Jansen, R. L., Opdam, F. L., Boot, H., Creemers, G. J., van Rooijen, J. M., Los, M., Vulink, A. J.E., Schut, H., van Meerten, E., Baars, A., Hamberg, P., Kapiteijn, E., Sommeijer, D. W., Punt, C. J.A., Koopman, M., Sub Tolakker, Afd Pedagogiek in diverse samenlevingen, Methodology and statistics for the behavioural and social sciences, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, MUMC+: MA Medische Oncologie (9), Interne Geneeskunde, Oncology, CCA - Cancer Treatment and Quality of Life, Sub Tolakker, Afd Pedagogiek in diverse samenlevingen, Methodology and statistics for the behavioural and social sciences, and Medical Oncology
Subjects: Male, 0301 basic medicine, THYMIDINE PHOSPHORYLASE, PREDICTOR, Pyrrolidines, ANTITUMOR-ACTIVITY, ECOG Performance Status, Trifluridine, chemistry.chemical_compound, 0302 clinical medicine, QUALITY-OF-LIFE, Antineoplastic Combined Chemotherapy Protocols, Netherlands, Aged, 80 and over, education.field_of_study, Metastatic colorectal cancer, Trifluridine/tipiracil, Feasibility, Hematology, General Medicine, Middle Aged, Prognosis, TAS-102, Drug Combinations, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, SURVIVAL, Population study, Original Article, Female, TRIAL, Colorectal Neoplasms, medicine.drug, Adult, medicine.medical_specialty, Anemia, Population, Neutropenia, Disease-Free Survival, 03 medical and health sciences, SDG 3 - Good Health and Well-being, NEUTROPENIA, Internal medicine, PERFORMANCE STATUS, medicine, Humans, Compassionate use, Uracil, education, Aged, Tipiracil, Performance status, business.industry, Leukopenia, medicine.disease, EFFICACY, 030104 developmental biology, chemistry, Surgery, business, Thymine
Abstract: BACKGROUND The RECOURSE trial showed clinical efficacy for trifluridine/tipiracil for refractory metastatic colorectal cancer patients. We assessed the feasibility and effectiveness of trifluridine/tipiracil in daily clinical practice in The Netherlands. METHODS Medical records of patients from 17 centers treated in the trifluridine/tipiracil compassionate use program were reviewed and checked for RECOURSE eligibility criteria. Baseline characteristics, safety, and survival times were compared, and prespecified baseline characteristics were tested in multivariate analyses for prognostic significance on overall survival (OS). RESULTS A total of 136 patients with a median age of 62 years were analyzed. Forty-three patients (32%) did not meet the RECOURSE eligibility criteria for not having received all prior standard treatments (n = 35, 26%) and/or ECOG performance status (PS) 2 (n = 12, 9%). The most common grade ≥3 toxicities were neutropenia (n = 44, 32%), leukopenia (n = 8, 6%), anemia (n = 7, 5%), and fatigue (n = 7, 5%). Median progression-free survival (PFS) and median OS were 2.1 (95% CI, 1.8-2.3) and 5.4 months (95% CI, 4.0-6.9), respectively. Patients with ECOG PS 2 had a worse median OS (3.2 months) compared to patients with ECOG PS 0-1 (5.9 months). ECOG PS, KRAS-mutation status, white blood cell count, serum lactate dehydrogenase, and alkaline phosphatase were prognostic factors for OS. CONCLUSIONS Our data show that treatment with trifluridine/tipiracil in daily clinical practice is feasible and safe. Differences in patient characteristics between our population and the RECOURSE study population should be taken into account in the interpretation of survival data. Our results argue against the use of trifluridine/tipiracil in patients with ECOG PS 2. FUNDING Johannes J.M. Kwakman received an unrestricted research grant from Servier.
Published: 2018

20. Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer

Author: Aggarwal, C., Meropol, N. J., Punt, C. J., Iannotti, N., Saidman, B. H., Sabbath, K. D., Gabrail, N. Y., Picus, J., Morse, M. A., Mitchell, E., Miller, M. C., and Cohen, S. J.
Published: 2013
Full Text: View/download PDF

21. Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer

Author: Pander, J., Wessels, J. A. M., Gelderblom, H., van der Straaten, T., Punt, C. J. A., and Guchelaar, H.-J.
Published: 2011
Full Text: View/download PDF

22. O-19 Feasibility of switching to S-1 upon other fluoropyrimidine-related cardiotoxicity during chemotherapy for solid tumors

Author: Osterlund, P., primary, Kinos, S., additional, Halonen, P., additional, Soveri, L., additional, Kwakman, R., additional, Salminen, T., additional, McDermott, R., additional, Pfeiffer, P., additional, Heervä, E., additional, Liposits, G., additional, Röckert, R., additional, Ålgars, A., additional, Ristamäki, R., additional, Kallio, R., additional, Sorbye, H., additional, Flygare, P., additional, Hagman, H., additional, Shah, C., additional, Teske, A., additional, Werkhoven, E. van, additional, Glimelius, B., additional, and Punt, C., additional
Published: 2020
Full Text: View/download PDF

23. SO-30 Adjuvant systemic chemotherapy versus active surveillance following upfront resection of isolated synchronous colorectal peritoneal metastases: Propensity score-matched analysis of a nationwide registry

Author: Rovers, K., primary, Bakkers, C., additional, Erning, F. van, additional, Burger, J., additional, Nienhuijs, S., additional, Simkens, G., additional, Creemers, G., additional, Hemmer, P., additional, Punt, C., additional, Lemmens, V., additional, Tanis, P., additional, and de Hingh, I., additional
Published: 2020
Full Text: View/download PDF

24. LBA-6 Safety, feasibility, tolerability, and preliminary efficacy of perioperative systemic therapy for resectable colorectal peritoneal metastases: Pilot phase of a randomised trial (CAIRO6)

Author: Rovers, K., primary, Bakkers, C., additional, Nienhuijs, S., additional, Burger, J., additional, Creemers, G., additional, Brandt-Kerkhof, A., additional, Tuynman, J., additional, Aalbers, A., additional, Wiezer, M., additional, Reuver, P. de, additional, Hemmer, P., additional, Grevenstein, W. van, additional, Erve, I. van 't, additional, Snaebjornsson, P., additional, Nederend, J., additional, Lahaye, M., additional, Dijkgraaf, M., additional, Punt, C., additional, Tanis, P., additional, and Hingh, I. de, additional
Published: 2020
Full Text: View/download PDF

25. P-79 C-PRECISE-01 study: A phase Ib/II trial of MEN1611, a PI3K inhibitor, and cetuximab in patients with PIK3CA mutated metastatic colorectal cancer failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimens

Author: Tabernero, J., primary, Fernandez, E. Elez, additional, Ghiringhelli, F., additional, Folprecht, G., additional, Curigliano, G., additional, Siena, S., additional, Cremolini, C., additional, Sobrero, A., additional, Kwiatek, M., additional, Keränen, S. Roselló, additional, Ahn, D., additional, Punt, C., additional, Laurent, D., additional, Ferrara, M., additional, Pellacani, A., additional, and Capriati, A., additional
Published: 2020
Full Text: View/download PDF

26. SO-19 S-1 is a cost-effective alternative to capecitabine in metastatic colorectal cancer

Author: van Oijen, M., primary, Kwakman, R., additional, and Punt, C., additional
Published: 2020
Full Text: View/download PDF

27. P-275 Quality of life and symptoms in patients undergoing CRS-HIPEC with or without perioperative systemic treatment for colorectal peritoneal metastases: Results from the randomised CAIRO6 trial

Author: Bakkers, C., primary, Rovers, K., additional, Rijken, A., additional, Mols, F., additional, Simkens, G., additional, Brandt-Kerkhof, A., additional, Tuynman, J., additional, Aalbers, A., additional, Kok, N., additional, Wiezer, M., additional, Reuver, P. de, additional, Grevenstein, W. van, additional, Hemmer, P., additional, Dijkgraaf, M., additional, Punt, C., additional, Tanis, P., additional, and Hingh, I. de, additional
Published: 2020
Full Text: View/download PDF

28. Implementation and outcomes of a national liver surgeons expert panel to determine secondary resectability in patients with initially unresectable colorectal liver metastases (CRLM)

Author: Swijnenburg, R., primary, Bolhuis, K., additional, Huiskens, J., additional, Van Lienden, K., additional, Engelbrecht, M., additional, Van Amerongen, M., additional, Heijmen, L., additional, Hermans, J., additional, Molenaar, Q., additional, Verhoef, C., additional, Grünhagen, D., additional, De Jong, K., additional, Klaase, J., additional, Dejong, C., additional, Kazemier, G., additional, Ruers, T., additional, De Wilt, H., additional, Rijken, A., additional, Gerhards, M., additional, Liem, M., additional, Patijn, G., additional, Punt, C., additional, and Van Gulik, T., additional
Published: 2020
Full Text: View/download PDF

29. The predictive and prognostic value of circulating endothelial cells in advanced colorectal cancer patients receiving first-line chemotherapy and bevacizumab

Author: Simkens, L. H. J., Tol, J., Terstappen, L. W. M. M., Teerenstra, S., Punt, C. J. A., and Nagtegaal, I. D.
Published: 2010
Full Text: View/download PDF

30. Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents

Author: Tol, J., Koopman, M., Miller, M. C., Tibbe, A., Cats, A., Creemers, G. J., Vos, A. H., Nagtegaal, I. D., Terstappen, L. W., and Punt, C. J.
Published: 2010
Full Text: View/download PDF

31. A prospective monitoring of fatal serious adverse events (SAEs) in a Dutch Colorectal Cancer Group (DCCG) phase III trial (CAIRO) in patients with advanced colorectal cancer

Author: Mol, L., Koopman, M., Ottevanger, P. B., and Punt, C. J.
Published: 2010

32. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer

Author: Cohen, S J, Punt, C J A, Iannotti, N, Saidman, B H, Sabbath, K D, Gabrail, N Y, Picus, J, Morse, M A, Mitchell, E, Miller, M C, Doyle, G V, Tissing, H, Terstappen, L W M M, and Meropol, N J
Published: 2009

33. DNA copy number profiles of primary tumors as predictors of response to chemotherapy in advanced colorectal cancer

Author: Postma, C, Koopman, M, Buffart, T E, Eijk, P P, Carvalho, B, Peters, G J, Ylstra, B, van Krieken, J H, Punt, C J A, and Meijer, G A
Published: 2009

34. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity

Author: Tol, J., Koopman, M., Rodenburg, C. J., Cats, A., Creemers, G. J., Schrama, J. G., Erdkamp, F. L. G., Vos, A. H., Mol, L., Antonini, N. F., and Punt, C. J. A.
Published: 2008

35. Chemotherapy response evaluation with FDG–PET in patients with colorectal cancer

Author: de Geus-Oei, L.F., van Laarhoven, H. W. M., Visser, E. P., Hermsen, R., van Hoorn, B. A., Kamm, Y. J. L., Krabbe, P. F. M., Corstens, F. H. M., Punt, C. J. A., and Oyen, W. J. G.
Published: 2008

36. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database

Author: Franko, J, Shi, Q, Meyers, J, Maughan, T, Adams, R, Seymour, M, Saltz, L, Punt, C, Koopman, M, Tournigand, C, Tebbutt, N, Diaz-Rubio, E, Souglakos, J, Falcone, A, Chibaudel, B, Heinemann, V, Moen, J, De Gramont, A, Sargent, D, Grothey, A, Group, Analysis And Research In Cancers Of The Digestive System (Arcad), and Oncology
Subjects: Adult, Male, Oncology, medicine.medical_specialty, Adolescent, Colorectal cancer, Clinical Trial, Phase III, Rectum, Metastasis, law.invention, 03 medical and health sciences, Phase III, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Journal Article, medicine, Clinical endpoint, Humans, Prospective Studies, Prospective cohort study, Peritoneal Neoplasms, Aged, Proportional Hazards Models, Aged, 80 and over, Proportional hazards model, business.industry, Middle Aged, Prognosis, medicine.disease, Clinical Trial, Clinical trial, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Randomized Controlled Trial, Female, 030211 gastroenterology & hepatology, Colorectal Neoplasms, business
Abstract: BACKGROUND: Patients with peritoneal metastatic colorectal cancer have reduced overall survival compared with patients with metastatic colorectal cancer without peritoneal involvement. Here we further investigated the effect of the number and location of metastases in patients receiving first-line systemic chemotherapy. METHODS: We analysed individual patient data for previously untreated patients enrolled in 14 phase 3 randomised trials done between 1997 and 2008. Trials were included if protocols explicitly pre-specified and solicited for patients with peritoneal involvement in the trial data collection process or had done a formal peritoneum-focused review of individual pre-treatment scans. We used stratified multivariable Cox models to assess the prognostic associations of peritoneal metastatic colorectal cancer with overall survival and progression-free survival, adjusting for other key clinical-pathological factors (age, sex, Eastern Cooperative Oncology Group (ECOG) performance score, primary tumour location [colon vs rectum], previous treatment, and baseline BMI). The primary endpoint was difference in overall survival between populations with and without peritoneal metastases. FINDINGS: Individual patient data were available for 10 553 patients. 9178 (87%) of 10 553 patients had non-peritoneal metastatic colorectal cancer (4385 with one site of metastasis, 4793 with two or more sites of metastasis), 194 (2%) patients had isolated peritoneal metastatic colorectal cancer, and 1181 (11%) had peritoneal metastatic colorectal cancer and other organ involvement. These groups were similar in age, ethnic origin, and use of targeted treatment. Patients with peritoneal metastatic colorectal cancer were more likely than those with non-peritoneal metastatic colorectal cancer to be women (565 [41%] of 1371 vs 3312 [36%] of 9169 patients; p=0·0003), have colon primary tumours (1116 [84%] of 1334 patients vs 5603 [66%]; p
Published: 2019

37. FDG-PET for prediction of survival of patients with metastatic colorectal carcinoma

Author: de Geus-Oei, L. F., Wiering, B., Krabbe, P. F. M., Ruers, T. J. M., Punt, C. J. A., and Oyen, W. J. G.
Published: 2006

38. Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study

Author: Koopman, M., Antonini, N. F., Douma, J., Wals, J., Honkoop, A. H., Erdkamp, F. L. G., de Jong, R. S., Rodenburg, C. J., Vreugdenhil, G., Akkermans-Vogelaar, J. M., and Punt, C. J. A.
Published: 2006

39. Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests

Author: Lesterhuis, W. J., de Vries, I. J. M., Schuurhuis, D. H., Boullart, A. C. I., Jacobs, J. F. M., de Boer, A. J., Scharenborg, N. M., Brouwer, H. M. H., van de Rakt, M. W. M. M., Figdor, C. G., Ruers, T. J., Adema, G. J., and Punt, C. J. A.
Published: 2006

40. A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer

Author: Rea, D. W., Nortier, J. W. R., Ten Bokkel Huinink, W. W., Falk, S., Richel, D. J., Maughan, T., Groenewegen, G., Smit, J. M., Steven, N., Bakker, J. M., Semiond, D., Kerr, D. J., and Punt, C. J. A.
Published: 2005

41. Irinotecan or oxaliplatin for first-line treatment of advanced colorectal cancer?

Author: Punt, C. J. A.
Published: 2005

42. Phase II study of E7070 in patients with metastatic melanoma

Author: Smyth, J. F., Aamdal, S., Awada, A., Dittrich, C., Caponigro, F., Schöffski, P., Gore, M., Lesimple, T., Djurasinovic, N., Baron, B., Ravic, M., Fumoleau, P., and Punt, C. J. A.
Published: 2005

43. Dendritic cell-based vaccines in cancer immunotherapy: an update on clinical and immunological results

Author: Lesterhuis, W. J., de Vries, I. J. M., Adema, G. J., and Punt, C. J. A.
Published: 2004

44. New options and old dilemmas in the treatment of patients with advanced colorectal cancer

Author: Punt, C. J. A.
Published: 2004

45. Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors

Author: Punt, C. J. A., Boni, J., Bruntsch, U., Peters, M., and Thielert, C.
Published: 2003

46. Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide)

Author: van Kesteren, Charlotte, Mathôt, R. A. A., Raymond, E., Armand, J. P., Fumoleau, P., Punt, C., Ravic, M., Wanders, J., Beijnen, J. H., and Schellens, J. H. M.
Published: 2002

47. Adjuvant interferon for melanoma

Author: Punt, C. J. A. and Eggermont, A. M. M.
Published: 2002

48. Limitations of cytokeratin 20 RT-PCR to detect disseminated tumour cells in blood and bone marrow of patients with colorectal cancer: expression in controls and downregulation in tumour tissue

Author: Vlems, F A, Diepstra, J H S, Cornelissen, I M H A, Ruers, T J M, Ligtenberg, M J L, Punt, C J A, van Krieken, J H J M, Wobbes, Th, and van Muijen, G N P
Published: 2002

49. Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study

Author: Punt, C. J. A., Keizer, H. J., Douma, J., Skovsgaard, T., Schüller, J., Muller, E. W., Ten Napel, C. H. H., Croles, J. J., Lochs, H., Zhang, J., and Hammershaimb, L.
Published: 2002

50. Integrated analysis of overall survival in two randomised studies comparing 5-fluorouracil/leucovorin with or without trimetrexate in advanced colorectal cancer

Author: Punt, C. J. A., Blanke, C. D., Zhang, J., and Hammershaimb, L.
Published: 2002

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

332 results on '"Punt, C."'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources